ImpediMed Limited (ASX:IPD)
ImpediMed Limited (ASX:IPD) is a medical company using bioimpedancespectroscopy (BIS) technology to generate data to maximise patient health.
ImpediMed produces a range of medical devices, including SOZO for multiple indications including heart failure, lymphoedema and protein calorie malnutrition.
SOZO Digital Health
Platform SOZO is the world's most advanced, non-invasive bioimpedancespectroscopy (BIS) device. It delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMeds BIS technology, SOZO measures 256 unique datapoints. Results are available immediately for easy access and sharing across an entire Health care system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heartfailure, and can be used to monitor and maintain overall health.
The Company was founded and remains headquartered in Brisbane, Australia. It also has US and European operations.